Abstract
Like most infections and certain inflammatory diseases, some therapeutic proteins cause a cytokine-mediated suppression of hepatic drug-metabolizing enzymes, which may lead to pharmacokinetic interactions with small-molecule drugs. We propose a new in vitro method to evaluate the whole blood–mediated effects of therapeutic proteins on drug-metabolizing enzymes in human hepatocytes cocultured with Kupffer cells. The traditional method involves treating hepatocyte cocultures with the therapeutic protein, which detects hepatocyte- and macrophage-mediated suppression of cytochrome P450 (P450). The new method involves treating whole human blood with a therapeutic protein to stimulate the release of cytokines from peripheral blood mononuclear cells (PBMCs), after which plasma is prepared and added to the hepatocyte coculture to evaluate P450 enzyme expression. In this study, human blood was treated for 24 hours at 37°C with bacterial lipopolysaccharide (LPS) or ANC28.1, an antibody against human T-cell receptor CD28. Cytokines were measured in plasma by sandwich immunoassay with electrochemiluminescense detection. Treatment of human hepatocyte cocultures with LPS or with plasma from LPS-treated blood markedly reduced the expression of CYP1A2, CYP2B6, and CYP3A4. However, treatment of hepatocyte cocultures with ANC28.1 did not suppress P450 expression, but treatment with plasma from ANC28.1-treated blood suppressed CYP1A2, CYP2B6, and CYP3A4 activity and mRNA levels. The results demonstrated that applying plasma from human blood treated with a therapeutic protein to hepatocytes cocultured with Kupffer cells is a suitable method to identify those therapeutic proteins that suppress P450 expression by an indirect mechanism—namely, the release of cytokines from PBMCs.
Footnotes
- Received July 22, 2014.
- Accepted October 17, 2014.
The design of this study is subject to U.S. patent 8846576.
Parts of this work were previously presented at the following meetings:
Parkinson A (2011) In vitro approaches to assessing the enzyme-suppressing effects of large molecule drugs. Second International Workshop on Regulatory Requirements and Current Scientific Aspects on the Preclinical and Clinical Investigation of Drug-Drug Interactions; 2011 May 1–3; Marbach Castle, Germany. Clinical Research Appliance, Radofzell, Germany;
Czerwinski M, Renneke C, Parker J, Pope C, Lyon K, Wiegand C, Neat J, Kazmi F, Buckley D, and Parkinson A (2011) An in vitro test system to evaluate drug-drug interactions with biologics. Seventeenth North American Regional ISSX Meeting; 2011 Oct 16–20; Atlanta, GA. International Society for the Study of Xenobiotics, Washington, DC;
Kazmi F (2012) An in vitro method to investigate drug-drug interactions with biologics. Second Annual Joint Symposium on: Biomarkers and Drug Development and Bioanalytical Issues; 2012 March 8; Langhorne, PA. Delaware Valley Drug Metabolism Discussion Group;
Kazmi F (2012) An in vitro method to investigate drug-drug interactions with biologics. Fifty-first Annual SOT Meeting; 2012 March 11–15; San Francisco, CA. Society of Toxicology, Reston, VA;
Kazmi F (2012) In vitro approaches to assess the enzyme-suppressing effects of biologics. Fifteenth International Conference on Drug-Drug Interactions; 2012 June 11–13; Seattle, WA. Institute for Scientific Communications, Columbia, MD.
This article has supplemental material available at dmd.aspetjournals.org.
- Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|